ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Aligos Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.84−0.02 (-0.41%)
Close on Oct 19, 2026
- Market cap
- $50.49M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Aligos Therapeutics has not reported a dividend
No dividend per share appears in Aligos Therapeutics's annual filings since fiscal 2018.